Autolus Therapeutics (AUTL) Cash from Investing Activities (2017 - 2025)

Autolus Therapeutics (AUTL) has 9 years of Cash from Investing Activities data on file, last reported at $86.5 million in Q4 2025.

• Quarterly Cash from Investing Activities rose 122.56% year-over-year to $86.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $158.5 million (up 140.16% YoY) and the FY2025 annual result came in at $158.5 million, up 140.16% from the prior year.
• Cash from Investing Activities rose to $86.5 million in Q4 2025, from $35.5 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $95.9 million in Q2 2025 to a low of -$383.6 million in Q4 2024.
• A 5-year average of -$13.3 million and a median of -$1.5 million in 2021 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2024 — Cash from Investing Activities slumped 25870.82% — and 2025, when it surged 11504.88%.
• Tracing AUTL's Cash from Investing Activities over 5 years: stood at -$1.6 million in 2021, then soared by 60.06% to -$633000.0 in 2022, then sank by 133.33% to -$1.5 million in 2023, then tumbled by 25870.82% to -$383.6 million in 2024, then jumped by 122.56% to $86.5 million in 2025.
• The last three Cash from Investing Activities figures came in at $86.5 million (Q4 2025), $35.5 million (Q3 2025), and $95.9 million (Q2 2025), per Business Quant data.